1. Scrip
  2. >>Therapy Areas

Sciele to acquire Addrenex for $29 million

 
• By Eleanor Malone

Sciele Pharma will pay $29 million in cash for Addrenex Pharmaceuticals, in a transaction which builds on a series of product licensing deals between the two US firms over the past few years.

Sciele Pharma will pay $29 million in cash for Addrenex Pharmaceuticals, in a transaction which builds on a series of product licensing deals between the two US firms over the past few years.

The immediate benefits for Sciele, itself acquired by Shionogi for $1.4 billion just over a year ago, include access to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapeutic Category

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 
• By Alaric DeArment

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.